Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Tubular breast carcinoma is a rare and unique subtype of invasive ductal carcinoma, accounting for less than 2% of all breast cancer cases. As a leading preclinical CRO, Alfa Cytology has dedicated extensive research efforts to understanding the intricacies of this disease and developing innovative therapeutic approaches.
Originating from the breast duct cells, tubular carcinoma is characterized by its distinct tubular architectural pattern and typically less aggressive behavior compared to other invasive breast cancers. Despite its rarity, this subtype presents distinct challenges in terms of accurate diagnosis and optimal treatment strategies.
Fig.1 A case of tubular breast carcinoma. (Metovic J., et al. 2021)
Tubular breast carcinoma is characterized by its heterogeneous nature, with diverse molecular profiles and varying responses to individual therapeutic agents. By combining targeted agents, immunotherapies, and traditional chemotherapeutics, researchers aim to target multiple signaling pathways and cellular processes simultaneously.
| Category | Therapeutics | Phase | NCT |
| Combination Therapies | Paclitaxel + Cisplatin + Epirubicin | NCT02879513 | |
| Paclitaxel + Cisplatin + EC to docetaxel or paclitaxel | NCT03201861 | ||
| Non-pegylated liposomal doxorubicin + Carboplatin + Paclitaxel | NCT02125344 | ||
| Nanoparticle-based Therapy | nab-Paclitaxel | NCT01583426 |
Tubular breast carcinoma is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for tubular breast carcinoma, including but not limited to the following.
Therapy Development
At Alfa Cytology, our comprehensive suite of oncology services and deep disease-specific expertise provide a powerful platform for accelerating the development of novel tubular breast carcinoma therapies. From molecular profiling and biomarker discovery to the establishment of robust preclinical models and the systematic evaluation of therapeutic candidates, our team of cancer experts is well-equipped to support researchers and clinicians at every stage of the drug development process. If you are interested in our service, please contact us.
Reference
